Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    The NIH’s Drug Repurposing Initiative: Will It Be a Waste?

    The NIH’s attempt to repurpose shelved development compounds and other older drugs is underway: The National Institutes of Health (NIH) today announced a new plan for boosting drug development: It has reached a deal with three major pharmaceutical companies to share abandoned experimental drugs with academic researchers so they can look for n… Read More
  • Academia (vs. Industry)

    A New Way to Kill Amoebas, From An Old Drug

    Here’s a good example of phenotypic screening coming through with something interesting and worthwhile: they screened against Entamoeba histolytica, the protozooan that causes amoebic dysentery and kills tens of thousands of people every year. (Press coverage here). It wasn’t easy. The organism is an anaerobe, which is a bad fit for mos… Read More
  • Academia (vs. Industry)

    A Molecular Craigslist?

    Mat Todd at the University of Sydney (whose open-source drug discovery work on schistosomiasis I wrote about here) has an interesting chemical suggestion. His lab is also involved in antimalarial work (here’s an update, for those interested, and I hope to post about this effort more specifically). He’s wondering about whether there̵… Read More
  • Academia (vs. Industry)

    Do Industrial Post-Doc Positions Work?

    A reader sends along this query, which I thought asked a very useful question: “. . .as a member of a growing biopharma company I am tasked with evaluating the effectiveness of industrial post-docs from both a business perspective and the post-doc’s experience. Specifically, we are considering adding one for a short-term (2yr) to add… Read More
  • Academia (vs. Industry)

    Different Worlds: A Last DHFR Paper Thought

    Inspired by a discussion with a colleague, I’m going to take one more crack at the recent discussion here about the J. Med. Chem. DHFR paper. Those of you with an interest in the topic, read on. Those whose interest has waned, or who never had much interest to start with, take heart: other topics… Read More
  • Academia (vs. Industry)

    Europe Wants Some of That Molecular Library Action

    We’ve talked about the NIH’s Molecular Libraries Initiative here a few times, mostly in the context of whether it reached its goals, and what might happen now that it looks as if it might go away completely. Does make this item a little surprising? Almost a decade ago, the US National Institutes of Health kicked… Read More
  • Academia (vs. Industry)

    Merck’s CALIBR Venture

    So the news is that Merck is now going to start its own nonprofit drug research institute in San Diego: CALIBR, the California Institute for Biomedical Research. It’ll be run by Peter Schultz of Scripps, and they’re planning to hire about 150 scientists (which is good news, anyway, since the biomedical employment picture out in… Read More
  • Academia (vs. Industry)

    Making the Move From Industry to Academia

    I have a reader who’s in the process of moving from an industrial setting to teaching medicinal chemistry. He wanted to know if I’d ever written about that topic, and I have to say, I don’t think there’s been a post dedicated to it yet. I know that many people have done just this (and… Read More
  • Academia (vs. Industry)

    More on the NIH’s Molecular Libraries Program

    I last wrote about the Molecular Libraries program here, as it was threatened with funding cuts. Now there’s a good roundup of opinion on it here, at the SLAS. The author has looked over the thoughts of the readership here, and also heard from several other relevant figures. Chris Lipinski echoes what several commenters here… Read More
  • Academia (vs. Industry)

    That Academic-Industrial Collaboration Panel

    Here’s the streaming video of the session I did at SLAS2012 on collaboration between academia and industry. I’m not sure how long it’ll be up, so if you want to see it, you probably should go ahead and check it out. A lot of people probably wish they could fast-forward (and pause) me during regular… Read More
...678...